162 related articles for article (PubMed ID: 37350558)
1. Development of a metabolite calculator for diagnosis of pancreatic cancer.
Choi M; Park M; Lee SH; Lee MJ; Paik YK; Jang SI; Lee DK; Lee SG; Kang CM
Cancer Med; 2023 Aug; 12(15):15933-15944. PubMed ID: 37350558
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
[TBL] [Abstract][Full Text] [Related]
3. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
Xiong Y; Shi C; Zhong F; Liu X; Yang P
Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
[TBL] [Abstract][Full Text] [Related]
4. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.
Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB
BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929
[TBL] [Abstract][Full Text] [Related]
5. [Integrated analysis of serum untargeted metabolomics and targeted bile acid metabolomics for identification of diagnostic biomarkers for colorectal cancer].
Wang X; Zhu Y; Zhou H; Huang Z; Chen H; Zhang J; Yang S; Chen G; Zhang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):443-453. PubMed ID: 37087590
[TBL] [Abstract][Full Text] [Related]
6. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
7. [Screening of serum oxysterol biomarkers for colon cancer by liquid chromatography-tandem mass spectrometry].
Ma Z; Li Z; Wang H; Wang R; Han X
Se Pu; 2022 Jun; 40(6):541-546. PubMed ID: 35616199
[TBL] [Abstract][Full Text] [Related]
8. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
10. Use of Metabolomics as a Complementary Omic Approach to Implement Risk Criteria for First-Degree Relatives of Gastric Cancer Patients.
Corona G; Cannizzaro R; Miolo G; Caggiari L; De Zorzi M; Repetto O; Steffan A; De Re V
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518896
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer detection using targeted plasma metabolomics.
Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
13. Metabolic signatures of hepatolithiasis using ultra-high performance liquid chromatography-tandem mass spectrometry.
Wang C; Yang J; Li E; Luo S; Sun C; Liao Y; Li M; Ge J; Lei J; Zhou F; Wu L; Liao W
Metabolomics; 2022 Aug; 18(9):69. PubMed ID: 35976530
[TBL] [Abstract][Full Text] [Related]
14. Targeted metabolomics analysis for serum Helicobacter pylori-positive based on liquid chromatography-tandem mass spectrometry.
Wang J; Shan J; Zhang Y; Shi Y; Lu D; Wu Y; Guo XP; Liu H; Wang J; Hu N
Biomed Chromatogr; 2023 Jun; 37(6):e5622. PubMed ID: 36898359
[TBL] [Abstract][Full Text] [Related]
15. Urinary metabolomic analysis of intrahepatic cholestasis of pregnancy based on high performance liquid chromatography/mass spectrometry.
Ma L; Zhang X; Pan F; Cui Y; Yang T; Deng L; Shao Y; Ding M
Clin Chim Acta; 2017 Aug; 471():292-297. PubMed ID: 28669684
[TBL] [Abstract][Full Text] [Related]
16. Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis.
Saraswat M; Joenväärä S; Seppänen H; Mustonen H; Haglund C; Renkonen R
Cancer Med; 2017 Jul; 6(7):1738-1751. PubMed ID: 28573829
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics Identifies Biomarker Signatures to Differentiate Pancreatic Cancer from Type 2 Diabetes Mellitus in Early Diagnosis.
Xu H; Zhang L; Kang H; Liu J; Zhang J; Zhao J; Liu S
Int J Endocrinol; 2021; 2021():9990768. PubMed ID: 34868309
[TBL] [Abstract][Full Text] [Related]
18. Ultra-High Performance Liquid Chromatography-Mass Spectrometry-based Serum Metabolomics for Early Diagnosis of Refractory Tumor-induced Osteomalacia: A Case-control Study.
Li X; Gong Y; Zhang Q; Ni X; Pang Q; Chi Y; Jiajue R; Cui L; Jiang X; Wang O; Xing X; Jiang Y; Li M; Xia W
J Clin Endocrinol Metab; 2023 Jul; 108(8):2016-2023. PubMed ID: 36718510
[TBL] [Abstract][Full Text] [Related]
19. A quantitative multimodal metabolomic assay for colorectal cancer.
Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
